Analysis Kancera: Capital raised for phase II

Kancera’s main project KAND567 has successfully completed its phase Ib study. The next step is a phase II study in acute myocardial infarction, which is funded through a rights issue, which includes warrants, that will be carried out in March. We maintain our previous target price of SEK 1.2. Read the full report here.